Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ongericimab in Hyperlipidemia
NCT04469673Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ongericimab in hyperlipidemia, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2019; status: completed.
02
Drugs
ongericimab
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT04469673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469673.